Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neoplasms, Germ Cell and Embryonal × Disulfiram × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioblastoma 6 Melanoma 3 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Breast Neoplasms 2 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Glioma 1 Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram 1

Interventions

Cisplatin 13 Etoposide 11 Paclitaxel 8 Cyclophosphamide 7 Carboplatin 7 Ifosfamide 6 etoposide phosphate 5 Granulocyte Colony-Stimulating Factor 5 Gemcitabine 5 pembrolizumab 4 fludarabine 4 Sirolimus 4 Bleomycin 4 fludarabine phosphate 3 Sunitinib 3 Oxaliplatin 3 Mesna 3 Melphalan 3 Filgrastim 3 Drug Therapy 3 Brentuximab Vedotin 3 Bevacizumab 3 Automobiles 3 130-nm albumin-bound paclitaxel 3 tremelimumab 2 sodium thiosulfate 2 ribociclib 2 pralsetinib 2 pegfilgrastim 2 durvalumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03950830 2023-10-04

DISGCT

National Cancer Institute, Slovakia

Phase 2 Completed

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡